QQQS - ETF AI Analysis
Top Page
Invesco NASDAQ Future Gen 200 ETF (QQQS)
Rating:57Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown strong gains so far this year and over the past month, indicating positive recent momentum.
Growth-Oriented Top Holdings
Many of the largest positions, especially in technology and health care, have delivered strong year-to-date performance, helping drive the fund’s returns.
Moderate Expense Ratio
The fund’s expense ratio is relatively low for a specialized, future-focused strategy, allowing investors to keep more of their returns.
Negative Factors
Heavy Sector Concentration
Nearly all assets are concentrated in health care and technology, which can increase risk if these growth sectors experience a downturn.
Limited Geographic Diversification
The ETF is overwhelmingly invested in U.S. companies, offering very little exposure to other countries and their markets.
Small Asset Base
The fund manages a relatively small amount of assets, which can lead to lower trading volume and potentially wider bid-ask spreads for investors.
QQQS vs. SPDR S&P 500 ETF (SPY)
AUM21.20M
RegionNorth America
Expense Ratio0.20%
Beta1.44
IssuerInvesco
Inception DateOct 13, 2022
Dividend Yield2.52%
Asset ClassEquity
Index TrackedNasdaq Innovators Completion Cap Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume6,548
30 Day Avg. Volume7,891
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
80.26Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering200
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
QQQS Summary
The Invesco NASDAQ Future Gen 200 ETF (QQQS) tracks the Nasdaq Innovators Completion Cap Index, focusing on about 200 smaller, fast-growing U.S. companies that are not in the big NASDAQ-100. It leans heavily toward health care and technology firms, including names like MaxLinear and Axcelis Technologies. Someone might invest in QQQS to seek long-term growth and to diversify beyond the largest, most familiar tech giants by owning many up-and-coming innovators at once. A key risk is that these smaller, growth-focused stocks can be very volatile and may go up and down more than the overall market.
How much will it cost me?The expense ratio for the Invesco NASDAQ Future Gen 200 ETF (QQQS) is 0.2%, which means you’ll pay $2 per year for every $1,000 invested. This is slightly higher than the average for passively managed ETFs because it focuses on a niche group of innovative small and mid-cap companies, requiring more specialized management.
What would affect this ETF?The QQQS ETF, with its focus on innovative small and mid-cap U.S. companies, could benefit from advancements in technology and healthcare, sectors that make up a significant portion of its holdings. However, it may face challenges if interest rates rise, as smaller companies often struggle with higher borrowing costs, or if economic conditions weaken, which could impact consumer spending and industrial growth. Regulatory changes in healthcare or technology could also influence the performance of its top holdings.
QQQS Top 10 Holdings
QQQS is heavily tilted toward U.S. health-care innovators, with names like ClearPoint Neuro, Cartesian Therapeutics, and Precigen doing much of the heavy lifting as their shares have been on a steady to rising path in recent months. Optical Cable and Quantum, though smaller positions, have also been sprinting ahead and giving the fund an extra boost. On the flip side, Myriad Genetics, Aquestive Therapeutics, and Quanterix are losing steam, acting as a drag. Overall, this is a niche, domestically focused bet on future-gen health and tech disruptors rather than today’s mega-cap stars.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Newell Brands | 0.87% | $180.15K | $2.09B | -4.73% | 49 Neutral | |
| Myriad Genetics | 0.75% | $155.88K | $428.79M | -7.41% | 41 Neutral | |
| Arqit Quantum | 0.75% | $154.66K | $424.27M | -44.48% | 41 Neutral | |
| ClearPoint Neuro | 0.74% | $153.49K | $532.91M | 50.18% | 59 Neutral | |
| Cybin | 0.73% | $149.88K | ― | ― | 37 Underperform | |
| Quanterix | 0.72% | $148.58K | $159.69M | -44.60% | 61 Neutral | |
| TriSalus Life Sciences | 0.71% | $145.98K | $250.58M | -20.60% | 54 Neutral | |
| Precigen | 0.69% | $142.10K | $1.72B | 263.51% | 48 Neutral | |
| Optical Cable | 0.67% | $139.08K | $197.73M | 705.80% | 42 Neutral | |
| Ligand Pharma | 0.67% | $137.83K | $5.51B | 128.02% | 60 Neutral |
QQQS Technical Analysis
Positive
―
Price Trends
41.62
Positive
38.39
Positive
36.14
Positive
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For QQQS, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 42.32, equal to the 50-day MA of 41.62, and equal to the 200-day MA of 36.14, indicating a bullish trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QQQS.
QQQS Peer Comparison
Comparison Results
Performance Comparison
QQQS
Invesco NASDAQ Future Gen 200 ETF
44.50
18.30
69.85%
OASC
OneAscent Small Cap Core ETF
―
―
―
SMOX
Horizon Small/Mid Cap Core Equity ETF
―
―
―
FSCS
First Trust Smid Capital Strength Etf
―
―
―
HSMV
First Trust Horizon Managed Volatility Small/Mid ETF
―
―
―
BCSM
Baron SMID Cap ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents